ANNEMARIE WASSERFALL

No ORCID on file · 60 papers in corpus
2009

A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…

2009

A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…

2009

A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…

2009

A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…

2009

A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…

2009

A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…

2009

A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…

2009

A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…

2009

A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…

2009

A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…

2009

A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…

2009

A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…

2009

A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…

2009

A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…

2009

A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…

2009

A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…

2009

A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…

2009

A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…

2009

A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…

2009

A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…

2009

A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…

2009

A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…

2009

A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…

2009

A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…

2009

A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetat…